Molecular Neurodegeneration Advances: A New Chapter in the Fight Against Neurodegenerative Diseases
Published in Neuroscience
The growing prevalence of neurodegenerative diseases casts a profound shadow over global health, particularly as populations age. Conditions such as Alzheimer’s and Parkinson’s disease strip individuals of their cognitive abilities, motor function, and independence – impacting millions of families worldwide. The urgency to understand, diagnose, and treat these complex disorders has never been greater.
With this critical need in mind, we are proud to introduce Molecular Neurodegeneration Advances (MN Advances), a newly launched open-access journal dedicated to accelerating progress in neurodegeneration research. As a sister journal to the well-established Molecular Neurodegeneration, MN Advances provides a dynamic platform for groundbreaking studies that span molecular, cellular, and systems-level investigations.
What Makes MN Advances Unique?
MN Advances is committed to publishing high-quality, peer-reviewed research that illuminates the intricate mechanisms driving neurodegenerative diseases. Our scope is broad and inclusive, covering:
- Clinically and pathologically defined conditions such as Alzheimer’s disease, Parkinson’s disease, vascular dementia, and related disorders.
- Proteinopathies and molecular signatures, including tauopathies, synucleinopathies, and TDP-43 proteinopathies.
- Acute neurodegenerative events like stroke, traumatic brain injury, and spinal cord injury, which often trigger long-term degenerative processes.
Our mission is clear: to foster scientific communication that translates fundamental discoveries into improved patient care. From identifying biomarkers for early diagnosis to developing innovative therapeutic strategies, MN Advances aims to be at the forefront of research that changes lives.
Launching Our First Collection:
The Molecular Landscape of Neurodegeneration: Emerging Paradigms and Therapeutic Horizons
To mark this exciting beginning, MN Advances proudly announces its inaugural Collection: “The Molecular Landscape of Neurodegeneration: Emerging Paradigms and Therapeutic Horizons”. This Collection brings together cutting-edge research and expert perspectives on:
- Molecular drivers of disease progression: organelle dysfunction, protein misfolding, aggregation, myelin integrity, and clearance pathways.
- Neuroimmune interactions: the role of microglia, astrocytes, and inflammatory signaling.
- Genetic and epigenetic insights: multi-omics approaches, precision medicine, and environmental risk factors.
- Therapeutic innovation: novel drug targets, delivery systems, and regenerative strategies.
This Collection reflects our commitment to advancing knowledge and inspiring new approaches to diagnosis and treatment. We welcome submissions that fall within the scope of the Collection before 06 August 2026. Join Us in Shaping the Future of Neurodegeneration Research.
MN Advances is more than a journal – it’s a collaborative space for scientists, clinicians, and innovators worldwide. By embracing open access, we ensure that every published article is freely available, accelerating the dissemination of knowledge and fostering global collaboration.
We invite you to explore our aims and scope, our inaugural Collection, and consider MN Advances as your trusted venue for publishing impactful research. Together, we can illuminate the molecular pathways of neurodegeneration and pave the way toward effective therapies.
Follow the Topic
-
Molecular Neurodegeneration Advances
This is an open-access, peer-reviewed journal dedicated to advancing research on neurodegeneration at the molecular, cellular, and systems levels.
Your space to connect: The Psychedelics Hub
A new Communities’ space to connect, collaborate, and explore research on Psychotherapy, Clinical Psychology, and Neuroscience!
Continue reading announcementRelated Collections
With Collections, you can get published faster and increase your visibility.
The Molecular Landscape of Neurodegeneration: Emerging Paradigms and Therapeutic Horizons
Rapid advances in molecular neuroscience have revealed new layers of complexity in the pathogenic mechanisms underlying neurodegenerative diseases. From the dysregulation of lipid and protein homeostasis to the convergence of genetic, epigenetic, and environmental risk factors, the molecular architecture of neurodegeneration is being reshaped by cutting-edge discoveries. Our first Collection, The Molecular Landscape of Neurodegeneration: Emerging Paradigms and Therapeutic Horizons, aims to synthesize these developments and highlight their translational potential for diagnosis and therapy.
This Collection welcomes contributions from leading experts across the field, covering a broad spectrum of molecular and cellular processes implicated in a wide range of neurodegenerative diseases. Topics of interest include, but are not limited to:
• Emerging insights into lipid metabolism and myelin integrity
• Novel mechanisms of protein aggregation and clearance
• The role of organelle dysfunction in neuronal vulnerability
• The interplay between vascular, immune, and metabolic pathways
This Collection supports and amplifies research related to SDG 3, Good Health and Well-Being.
All submissions in this collection undergo the journal’s standard peer review process. Similarly, all manuscripts authored by a Guest Editor(s) will be handled by the Editor-in-Chief. As an open access publication, this journal levies an article processing fee (details here). We recognize that many key stakeholders may not have access to such resources and are committed to supporting participation in this issue wherever resources are a barrier. For more information about what support may be available, please visit OA funding and support, or email OAfundingpolicy@springernature.com or the Editor-in-Chief.
Publishing Model: Open Access
Deadline: Aug 06, 2026
Please sign in or register for FREE
If you are a registered user on Research Communities by Springer Nature, please sign in